(VREX) as a Liquidity Pulse for Institutional Tactics
This article provides an institutional tactical analysis for Varex Imaging Corporation (NASDAQ: VREX), highlighting weak near and mid-term sentiment but a strong long-term outlook. It details AI-generated trading strategies including position, momentum breakout, and risk hedging, alongside multi-timeframe signal analysis and risk-reward setups. The analysis offers specific entry, target, and stop-loss levels for different trading approaches.
Varex Imaging Stockholders Reelect Directors, Back Pay Plan and Deloitte at 2026 Virtual AGM
Varex Imaging (NASDAQ: VREX) held its 2026 Annual Meeting of Stockholders virtually, where shareholders reelected all seven director nominees, approved the advisory vote on named executive officer compensation, and ratified Deloitte & Touche LLP as the company’s independent auditor for fiscal 2026. Approximately 92% of outstanding common stock was represented, establishing a quorum for the meeting led by independent board chair Walter Rosebrough. The final vote tallies will be filed with the SEC within four business days.
Varex Imaging (NASDAQ:VREX) Stock Rating Lowered by Wall Street Zen
Wall Street Zen downgraded Varex Imaging (NASDAQ:VREX) from a "strong-buy" to a "buy" rating, despite the company beating its recent quarterly earnings estimates with $0.19 EPS against an expected $0.14. The consensus rating from other analysts remains a "Hold" with a target price of $16.17. Varex Imaging reported revenue of $209.6 million and provided Q2 2026 guidance, but still faces a negative net margin and P/E ratio.
Varex Imaging (VREX) Returns To Quarterly Profit Challenging Persistent Loss Narrative
Varex Imaging (VREX) reported a return to quarterly profit in fiscal Q1 2026 with net income of US$2.3 million and revenue of US$209.6 million, challenging its persistent loss narrative. Despite a five-year trend of growing losses and modest revenue growth, bulls point to a low P/S ratio and a valuation below DCF fair value as potential upside. Bears, however, highlight thin interest coverage and volatility in net income, suggesting the profit may be a temporary blip.
Varex Imaging Corporation (NASDAQ:VREX) Q1 2026 Earnings Call Transcript
Varex Imaging Corporation (NASDAQ: VREX) reported a strong start to fiscal year 2026, with Q1 revenue of $210 million, up 5% year-over-year, driven by a 17% increase in their Industrial segment. The company's Medical segment remained stable, with increased customer engagement on new platforms and an optimistic outlook for future demand, particularly in CT and general radiography. Varex is also seeing significant traction in its Industrial segment, especially in cargo security systems and photon counting detectors for industrial applications, and is making strategic investments in manufacturing facilities in India to support global growth and market competitiveness.
Earnings call transcript: Varex Imaging beats Q1 2026 EPS forecast
Varex Imaging (VREX) reported strong Q1 FY2026 results, surpassing analyst expectations with an EPS of $0.19 against a forecast of $0.14, and revenue of $210 million, exceeding the $205.48 million forecast. The company saw a 5% year-over-year revenue increase, driven by growth in both medical and industrial segments, and its stock gained 1.85% in aftermarket trading. Varex highlighted positive customer engagement, particularly in new product development and photon counting technologies, and is focused on expanding manufacturing capabilities in India.
Varex Imaging Corp (NASDAQ:VREX) Beats Profit Estimates as Industrial Segment Drives Growth
Varex Imaging Corp (NASDAQ:VREX) exceeded profit expectations in its first fiscal quarter of 2026, driven by strong growth in its Industrial segment, despite revenue slightly missing estimates. Non-GAAP EPS reached $0.19, surpassing analyst predictions of $0.14, while revenue totaled $209.6 million. The company's shares reacted cautiously positive, trading higher in after-market activity, as the Industrial segment's 17% year-over-year growth offset the flat Medical segment performance.
Varex Announces Financial Results for First Quarter Fiscal Year 2026
Varex Imaging Corporation reported solid Q1 FY2026 financial results with revenues of $210 million, a 5% increase year-over-year, driven by strength in its cargo systems business. Non-GAAP diluted EPS increased to $0.19. The company provided Q2 FY2026 guidance, expecting revenues between $210 million and $225 million and non-GAAP EPS between $0.15 and $0.25.
Y Intercept Hong Kong Ltd Sells 318,294 Shares of Varex Imaging $VREX
Y Intercept Hong Kong Ltd significantly reduced its stake in Varex Imaging (NASDAQ:VREX) by selling 318,294 shares, cutting its position by 92.6% to 25,303 shares. Despite this large sale, other institutional investors like Pzena Investment Management and Qube Research & Technologies increased their holdings in Varex. The company recently surpassed earnings and revenue estimates, but analyst sentiment remains mixed with an average "Hold" rating.
Can Varex Imaging Sustain Its Recent Rally?
Varex Imaging Corporation (US92214X1063) is set to release its Q1 2026 financial results on February 10, with investors closely watching to see if the company can maintain its recent stock rally. The company delivered strong Q4 2025 results, beating EPS and revenue estimates, but analysts are more conservative for Q1 2026, anticipating $0.14 EPS on $208 million revenue. The report and subsequent annual shareholder meeting will be crucial for the stock's future trajectory.
It Looks Like Varex Imaging Corporation's (NASDAQ:VREX) CEO May Expect Their Salary To Be Put Under The Microscope
Varex Imaging Corporation's CEO, Sunny Sanyal, may face scrutiny regarding his compensation due to the company's recent poor performance, with EPS falling by 97% over three years and shareholders experiencing a 25% loss. His total compensation of US$4.6m is 68% above the industry average for companies of similar market capitalization. Shareholders are expected to address this at the upcoming Annual General Meeting on February 12th.
(VREX) Risk Channels and Responsive Allocation
This article provides an in-depth analysis of Varex Imaging Corporation (NASDAQ: VREX), highlighting neutral near and mid-term readings but a positive long-term bias. It outlines distinct trading strategies (Long, Momentum Breakout, Short Risk Hedging) based on AI models, complete with entry/exit points and risk parameters. The analysis also includes multi-timeframe signal analysis, support, and resistance levels for VREX.
It Looks Like Varex Imaging Corporation's (NASDAQ:VREX) CEO May Expect Their Salary To Be Put Under The Microscope
Varex Imaging Corporation's CEO, Sunny Sanyal, may face scrutiny regarding his compensation at the upcoming AGM due to the company's disappointing performance. Over the past three years, EPS has fallen by 97%, and shareholders have experienced a 25% loss, while Sanyal's total compensation of US$4.6 million is 68% above the industry average for companies of similar size. Shareholders will have the opportunity to influence executive remuneration through voting given the decline in company performance and share price.
Varex Imaging Faces Financial Strain Amidst Potential Goodwill Impairment Charges
Varex Imaging Corporation is facing potential financial strain due to a significant decline in its stock price and market capitalization, which has fallen below its net tangible assets. This situation increases the risk of goodwill impairment charges, previously noted by auditors, which could further impact the company's financial results and investor confidence.
Jefferies raises Varex Imaging stock price target to $14.50 on market recovery
Jefferies has raised its price target for Varex Imaging (NASDAQ: VREX) to $14.50 from $12.00, maintaining a Hold rating due to expected improvements in medical end-markets and growth in industrial segments. The firm noted Varex's resilience despite past challenges and highlighted strong progress in PCD, Industrial Systems, and India Radiography. This follows Varex's Q4 2025 earnings, which surpassed analyst expectations in both EPS and revenue.
Jefferies raises Varex Imaging stock price target to $14.50 on market recovery
Jefferies has increased its price target for Varex Imaging (NASDAQ:VREX) to $14.50 from $12.00, while maintaining a Hold rating. This adjustment reflects expected improvements in medical markets and growth in industrial segments, particularly security inspection systems, with analysts anticipating the company to be profitable this fiscal year. Despite past challenges, Varex has shown strong stock performance and recently surpassed Q4 2025 earnings and revenue expectations.
Varex Imaging Corporation (VREX) Stock Analysis: Uncovering a 23% Upside Potential in the Medical Devices Sector
Varex Imaging Corporation (VREX) is highlighted as a key player in the medical devices sector with a market capitalization of $586.03 million. Despite a recent slight dip in stock performance, the company shows promising revenue growth of 11.30% and a healthy free cash flow of $39.5 million. Analysts maintain a positive outlook with an average target price suggesting a 23.03% upside, positioning Varex as an attractive opportunity for growth-oriented investors.
Varex Schedules First Quarter Fiscal Year 2026 Earnings Release and Conference Call
Varex Imaging Corporation (Nasdaq: VREX) has announced that it will release its unaudited financial results for the first quarter of fiscal year 2026 on Tuesday, February 10, 2026, after market close. A conference call and webcast will follow at 3:00 pm Mountain Time on the same day, accessible via their investor relations website. The webcast and a replay will be available for a limited period after the call.
Varex Imaging outlines stable China outlook and targets growth in Industrial segment for 2026
Varex Imaging has provided a stable outlook for its operations in China, anticipating continued growth in the medical sector despite macroeconomic challenges. The company is actively pursuing expansion in its Industrial segment, projecting it to become a significant revenue contributor by 2026. This strategic focus aims to diversify Varex Imaging's revenue streams and capitalize on emerging opportunities in industrial imaging applications.
(VREX) Movement as an Input in Quant Signal Sets
This article analyzes Varex Imaging Corporation (NASDAQ: VREX) using AI models, highlighting strong sentiment and testing resistance. It offers institutional trading strategies for different risk profiles, including long, breakout, and short setups with specific entry, target, and stop-loss levels. The analysis also provides multi-timeframe signal strengths, support, and resistance levels for near, mid, and long-term horizons.
Varex Imaging joins CJS ‘New Ideas for the New Year’ virtual conference
Varex Imaging Corporation announced its participation in the CJS Securities 26th Annual New Ideas for the New Year Virtual Conference. Management is scheduled to present on Wednesday, January 14, 2026, at 3:50 PM ET. Varex Imaging is a leading innovator and manufacturer of X-ray imaging components used in medical, industrial, and security applications.
Varex to Participate in CJS Securities 26th Annual New Ideas for the New Year Conference
Varex Imaging Corporation announced its management is scheduled to present at the CJS Securities 26th Annual New Ideas for the New Year Virtual Conference on Wednesday, January 14, 2026, at 3:50 PM ET. A webcast of the presentation will be available on Varex’s website. Varex is a leading innovator and manufacturer of X-ray imaging components for medical, industrial, and security applications.
Varex Imaging Shares Surge on Robust Quarterly Performance and Strategic Expansion
Varex Imaging Corporation reported strong Q4 results, exceeding analyst expectations with $0.37 EPS and $228.90 million in revenue, driven by a 25% industrial segment growth. Institutional investors, including Squarepoint Ops LLC, significantly increased their holdings, signaling renewed confidence. The company also expanded operations with a new production facility in India and provided Q1 2026 revenue guidance between $200 million and $215 million, with Oppenheimer reiterating an $18.00 price target.
Should Value Investors Buy VAREX IMAGING (VREX) Stock?
This article analyzes VAREX IMAGING (VREX) stock from a value investing perspective, highlighting its Zacks Rank #2 (Buy) and "A" grade for Value. It examines key valuation metrics such as P/E, P/B, and P/S ratios, comparing them to industry averages to suggest that VREX may be undervalued. The report concludes that VREX stands out as a strong value stock based on its valuation and earnings outlook.
Oppenheimer lowers Varex Imaging stock price target to $18 from $23
Oppenheimer reduced its price target for Varex Imaging (NASDAQ:VREX) to $18 from $23, while maintaining an Outperform rating. This adjustment follows Varex's strong Q4 fiscal 2025 revenue report of $229 million, surpassing estimates, and the company's initiation of radiographic detector production in India. Despite the lowered target, Oppenheimer views Varex as a "deep-value name" with significant upside potential and analysts predict a return to profitability this fiscal year.
Varex Imaging Corporation (NASDAQ:VREX) Q4 2025 Earnings Call Transcript
Varex Imaging Corporation (NASDAQ: VREX) reported strong Q4 and full fiscal year 2025 results, exceeding earnings expectations with Q4 revenue of $229 million, up 11% year-over-year. The medical segment saw growth driven by global CT tube sales, while the industrial segment achieved its highest revenue ever at $77 million, fueled by security screening demand. The company is advancing growth initiatives, including photon counting technology and expanding manufacturing in India, and projects continued revenue growth for fiscal year 2026.
Varex Imaging Beats Expectations With Strong Quarterly Gains
Varex Imaging outperformed Wall Street's Q4 forecasts for 2025, driven by strong sales in both medical and industrial markets with revenue reaching $229 million and non-GAAP earnings per share of $0.37. The company's innovation in photon counting tech and international product launches are contributing to a positive investor outlook, with analysts now rating it a buy. Despite cautious Q1 guidance, Varex sees steady demand and a strong future in the medical imaging sector, buoyed by its diverse market performance.
Earnings call transcript: Varex Imaging Q4 2025 beats estimates, shares rise
Varex Imaging Corp (VREX) reported strong Q4 2025 results, with an EPS of $0.37 and revenue of $229 million, both surpassing analyst estimates. This performance led to a 3.76% increase in stock price during after-hours trading, driven by growth in both medical and industrial segments and strategic initiatives like photon counting CT technology and manufacturing expansion in India. The company anticipates continued growth in fiscal year 2026, especially in its medical business outside China and its industrial segment, despite modeling flat revenue from China.
Varex Imaging Shares Fall 13% Despite Q4 Revenue Growth; FY26 Outlook Soft
Varex Imaging Corporation (VREX) saw its shares fall 13.28% despite reporting 11% year-over-year revenue growth in Q4 2025, reaching $229 million, and full-year revenue of $845 million. The decline was attributed to a net loss of $1.70 per share for FY25 and cautious FY26 guidance, expecting Q1 revenues of $200 million to $215 million and adjusted EPS of $0.05 to $0.25, impacted by underlying pressure in its medical components business. Investors reacted to the mixed results and conservative outlook, leading to heavy trading volume.
VREX: Varex Imaging Receives Consistent 'Buy' Rating from B. Ril
B. Riley Securities has reiterated its 'Buy' rating for Varex Imaging (VREX) and maintained a price target of $16.00, signaling a consistent positive outlook for the company. This follows a previous upgrade by analyst Kyle Bauser, who raised the price target from $12.00 to $16.00. Wall Street analysts forecast an average target price of $17.80 for VREX, implying a 77.73% upside from its current price, with GuruFocus estimating a fair value of $17.63.
Varex Imaging Corporation Announces Q4 and FY25 Financial Results
Varex Imaging Corporation reported strong financial results for Q4 and fiscal year 2025, with revenues increasing by 11% and 4% respectively. The growth was driven by global CT tube sales in the Medical segment and significant performance in the Industrial segment. The company also highlighted advancements in key growth initiatives and provided guidance for Q1 FY26.
Varex Imaging shares rise as fourth quarter results exceed expectations
Varex Imaging Corporation reported fourth-quarter earnings and revenue that significantly surpassed analyst expectations, driven by strong performance in its Medical and Industrial segments. The company posted adjusted earnings of $0.37 per share and revenue of $229 million, leading to a 2% rise in its shares in after-hours trading. Varex also provided optimistic first-quarter fiscal 2026 guidance, with anticipated revenue between $200 million and $215 million and adjusted earnings per share between $0.05 and $0.25.
Varex Announces Financial Results for Fourth Quarter and Fiscal Year 2025
Varex Imaging Corporation reported strong financial results for Q4 and fiscal year 2025, with Q4 revenues reaching $229 million, an 11% year-over-year increase, driven by medical CT tube sales and significant growth in their industrial segment. Fiscal year 2025 revenues totaled $845 million, up 4% year-over-year, with non-GAAP EBITDA growing 37% to $122 million and non-GAAP EPS rising 73% to $0.90. The company provided Q1 fiscal year 2026 guidance, expecting revenues between $200 million and $215 million, and non-GAAP net earnings per diluted share between $0.05 and $0.25.
Varex Imaging Corp SEC 10-K Report
Varex Imaging Corporation released its 2025 10-K report, showcasing significant financial growth with total revenues of $844.6 million, a 4% increase from 2024, driven by both Medical and Industrial segments. Despite a net loss of $(69.9) million due to a $93.9 million goodwill impairment charge, the company highlights strategic initiatives including localized manufacturing, capital management, and R&D investment to mitigate risks and drive future growth. Varex aims to expand its market presence, particularly in China's CT system market, and explore new applications like food sterilization.
Varex Schedules Fourth Quarter and Fiscal Year 2025 Earnings Release and Conference Call
Varex Imaging Corporation announced it will release its unaudited financial results for the fourth quarter and fiscal year 2025 on Tuesday, November 18, 2025, after market close. A conference call will follow at 3:00 pm Mountain Time, accessible via webcast on the company's website and by phone. An archived webcast and phone replay will also be available for a limited time.
Dimensional Fund Advisors LP Reduces Stake in Varex Imaging Corp
Dimensional Fund Advisors LP reduced its stake in Varex Imaging Corp (VREX) by 135,434 shares on September 30, 2025, decreasing its total holding to 1,992,611 shares. This transaction, executed at $12.40 per share, represents a minor adjustment to Dimensional's portfolio. Varex Imaging Corp, a medical device company, faces financial scrutiny with a low GF Value, despite strong momentum.
Varex Imaging Corporation (VREX) Stock Analysis: Exploring a 52% Potential Upside for Investors
Varex Imaging Corporation (VREX) stands out in the healthcare sector, specializing in X-ray imaging components. Despite current financial hurdles such as revenue contraction and negative EPS, analysts project a significant potential upside of approximately 52%, with an average target price of $17.80. Investors should carefully assess Varex's strategic advantages, including a diverse product portfolio and positive analyst sentiment, against its financial challenges, while conducting thorough due diligence.
Varex Imaging (VREX) Bounced Back from Liberation Day Sell-Off - Yahoo
Varex Imaging Corporation (VREX) saw a significant recovery in its stock price during Q3 2025, returning 43.02% after a previous sell-off. This bounce-back was attributed to investors realizing the tariff impact would be less severe than anticipated, the improvement in its China business, and the company's flexibility to move production. RAM Smid Composite, an investment management company, continues to view VREX as undervalued, citing an overlooked healthcare CT market recovery and growing security screening offerings.
Varex Imaging $VREX Shares Purchased by Wealth Enhancement Advisory Services LLC
Wealth Enhancement Advisory Services LLC increased its stake in Varex Imaging (VREX). Several other institutional investors also adjusted their positions in VREX, with significant changes reported by GAMMA Investing LLC, SG Americas Securities LLC, and Allspring Global Investments Holdings LLC. Analysts have maintained positive ratings for Varex Imaging, with B. Riley reaffirming a "buy" rating and setting a $16.00 target price.
Medical Imaging Leader Varex (VREX) to Share Strategic Updates at Sidoti Small Cap Virtual Conference
Varex Imaging Corporation (Nasdaq: VREX) announced it will present at the Sidoti Small Cap Virtual Conference on Wednesday, September 17, 2025, at 3:15 PM ET. The company, a leading innovator in X-ray imaging components and systems, will share strategic updates during its presentation. A webcast of the event will be available on Varex’s website.
Does VAREX IMAGING (VREX) Have the Potential to Rally 71.44% as Wall Street Analysts Expect?
Shares of VAREX IMAGING (VREX) have seen a 23.2% gain recently, and Wall Street analysts project a potential upside of 71.4% with a mean price target of $16.75. While a consensus price target provides a useful metric, investors should also consider the tight clustering of price targets, indicated by a low standard deviation, as a sign of analyst agreement. Furthermore, increasing optimism among analysts regarding the company's earnings prospects, evidenced by higher EPS estimate revisions and a Zacks Rank #2 (Buy), suggests legitimate reasons for a potential stock upside.
Varex Imaging Corporation (NASDAQ:VREX) Just Reported Earnings, And Analysts Cut Their Target Price
Varex Imaging Corporation (NASDAQ:VREX) reported third-quarter results, showing a 32% jump in share price despite statutory losses per share increasing significantly. Following the earnings report, analysts cut their target price by 22% to US$16.60 and revised down their EPS forecasts for 2026, indicating a decline in sentiment. While revenue estimates were reconfirmed, Varex Imaging's expected growth is slower than the wider industry.
SDHI to make cargo inspection systems for US-based Varex
Swan Defence and Heavy Industries (SDHI) has partnered with US-based Varex Imaging Corporation to exclusively manufacture high-energy cargo inspection systems at its facility in Pipavav, Gujarat. This collaboration aims to meet the increasing demand for advanced security inspection systems in India and supports the "Make in India" initiative for indigenous manufacturing. SDHI, a shipbuilding and heavy fabrication company, will produce these systems which are designed to inspect all types of cargo at land and sea ports.
Swan Defence Hits 52-Week High After Deal With US-Based Varex To Make Cargo Scanners
Swan Defence and Heavy Industries (SDHI) has partnered with US-based Varex Imaging Corporation to manufacture advanced cargo and vehicle inspection systems in India, leading to a new 52-week high for its shares. This collaboration supports the "Make in India" initiative and addresses domestic demand for sophisticated inspection technology, despite recent trade tensions between India and the US. The company's stock has seen a significant 793% surge year-to-date since its re-listing in January 2025.
Varex Imaging launches second manufacturing facility at AMTZ
Varex Imaging, through its subsidiary Varex Imaging Manufacturing India Private Limited, has inaugurated its second advanced manufacturing facility at the Andhra Pradesh MedTech Zone (AMTZ). This expansion underscores Varex's long-term commitment to India's MedTech sector and aims to establish India as a global hub for imaging technology. The new facility will localize the production of Cesium Iodide (CsI) coating and medical-grade glass tubes for X-ray and CT imaging, strengthening India's self-reliance in medical imaging hardware and positioning it as a key exporter.
Insider Sell Alert: Jay Kunkel Sells Shares of Varex Imaging Cor
Jay Kunkel, a Director at Varex Imaging Corp (VREX), sold 2,575 shares of the company on June 18, 2025, reducing his holdings to 22,477 shares. This transaction is part of a trend of 4 insider sells against 2 insider buys for VREX over the past year. Varex Imaging Corp is considered a "Possible Value Trap" based on its GF Value, with shares trading at $7.77, below the estimated intrinsic value of $15.35.
These 4 Measures Indicate That Varex Imaging (NASDAQ:VREX) Is Using Debt Extensively
Varex Imaging Corporation (NASDAQ:VREX) shows extensive use of debt, with net debt at US$344.2m as of April 2025, up from US$442.9m a year ago. The company's liabilities significantly outweigh its cash and short-term receivables, and its interest cover is weak at 2.2, indicating high leverage. While it generates decent free cash flow, its declining EBIT and high debt levels suggest potential risks for shareholders.
Lacklustre Performance Is Driving Varex Imaging Corporation's (NASDAQ:VREX) 32% Price Drop
Varex Imaging Corporation (NASDAQ:VREX) shares have dropped 32% in the last month, contributing to a 51% loss over the past year. The company's low price-to-sales (P/S) ratio of 0.4x, compared to an industry average of 3.1x, reflects its declining revenue and weak growth forecasts. Analysts predict only 1.6% revenue growth for Varex Imaging next year, significantly trailing the industry's projected 11% growth, which explains the market's dampened enthusiasm and the stock's poor performance.
Varex Imaging Corp divulga resultados do trimestre encerrado em 31 de dezembro - Resumo de lucros
Varex Imaging Corp (VREX) reported adjusted quarterly earnings of 7 cents per share for the quarter ending December 31, exceeding analysts' average expectation of 4 cents per share. The company's revenue increased by 15.2% year-over-year to $218.80 million, surpassing the estimated $202.15 million. Despite the positive adjusted earnings and revenue growth, the company reported a net loss of 1 cent per share and a quarterly loss of $300,000.
Varex Management to Participate in Upcoming Investor Conferences
Varex Imaging Corporation announced that its management will participate in three upcoming investor conferences in June 2024, including the Jefferies Global Healthcare Conference, the Goldman Sachs 45th Annual Global Healthcare Conference, and the Sidoti June 2024 Virtual Small Cap Conference. Details for accessing these events are provided on the Varex Imaging website. The article also includes company information and investor contact details.
